Trial Outcomes & Findings for Comparison of Day 19 and Day 20 Artificial FET (NCT NCT02788097)
NCT ID: NCT02788097
Last Updated: 2017-02-03
Results Overview
\>30IU/L of serum βhCG on day 14 of cycle
Recruitment status
TERMINATED
Study phase
NA
Target enrollment
130 participants
Primary outcome timeframe
1 year
Results posted on
2017-02-03
Participant Flow
Participant milestones
| Measure |
Progesterone + 4
the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
Progesterone supplementation: artificial frozen embryo transfers
61 patients randomized to this group
|
Progesterone + 5
the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
Progesterone supplementation: artificial frozen embryo transfers
69 patients randomized to this group
|
|---|---|---|
|
Overall Study
STARTED
|
61
|
69
|
|
Overall Study
COMPLETED
|
61
|
69
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Comparison of Day 19 and Day 20 Artificial FET
Baseline characteristics by cohort
| Measure |
Progesterone + 4
n=61 Participants
the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
Progesterone supplementation: artificial frozen embryo transfers
|
Progesterone + 5
n=69 Participants
the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
Progesterone supplementation: artificial frozen embryo transfers
|
Total
n=130 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
61 Participants
n=93 Participants
|
69 Participants
n=4 Participants
|
130 Participants
n=27 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Age, Continuous
|
28.2 years
STANDARD_DEVIATION 4.3 • n=93 Participants
|
28.5 years
STANDARD_DEVIATION 3.2 • n=4 Participants
|
28.35 years
STANDARD_DEVIATION 3.75 • n=27 Participants
|
|
Gender
Female
|
61 Participants
n=93 Participants
|
69 Participants
n=4 Participants
|
130 Participants
n=27 Participants
|
|
Gender
Male
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
|
Region of Enrollment
Turkey
|
61 participants
n=93 Participants
|
69 participants
n=4 Participants
|
130 participants
n=27 Participants
|
PRIMARY outcome
Timeframe: 1 year\>30IU/L of serum βhCG on day 14 of cycle
Outcome measures
| Measure |
Progesterone + 4
n=61 Participants
the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
Progesterone supplementation: artificial frozen embryo transfers
61 patients randomized to this group
|
Progesterone + 5
n=69 Participants
the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
Progesterone supplementation: artificial frozen embryo transfers
69 patients randomized to this group
|
|---|---|---|
|
Biochemical Pregnancy
|
52.5 percentage of participants
|
79.7 percentage of participants
|
Adverse Events
Progesterone + 4
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Progesterone + 5
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place